Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Roivant Sciences operates as a biopharmaceutical holding company that incubates and develops subsidiary companies ('Vants') focused on commercializing novel therapeutics. The company's most significant asset is Immunovant (IMVT), which is developing batoclimab for myasthenia gravis and thyroid eye disease, with pivotal trial data expected in 2026-2027. Roivant's business model centers on creating value through strategic spin-offs, partnerships, and milestone payments from its portfolio companies rather than traditional drug sales.
Roivant generates returns by identifying undervalued or de-risked drug candidates, forming subsidiary companies around specific therapeutic programs, advancing them through clinical development, and monetizing through partnerships, royalties, or public market spin-offs. The company maintains equity stakes in subsidiaries while providing shared infrastructure, regulatory expertise, and capital allocation. With minimal traditional revenue ($0M TTM) and high operating losses (-$800M cash burn), value creation depends entirely on clinical trial success and subsequent commercialization or partnership deals. The 96.9% gross margin reflects the asset-light model with minimal COGS, while the -3453% operating margin shows heavy R&D investment across the portfolio.
Immunovant batoclimab Phase 3 trial readouts for myasthenia gravis (ASCEND-MG) and thyroid eye disease (ASCEND-TED) expected 2026-2027
FDA regulatory milestones and potential approvals for lead programs across subsidiary portfolio
Strategic partnership announcements, licensing deals, or acquisition offers for subsidiary companies
Subsidiary spin-off events and subsequent equity value realization (Immunovant represents significant embedded value)
Clinical trial enrollment rates, safety data, and interim efficacy signals from mid-to-late stage programs
Binary clinical trial outcomes create extreme volatility - single Phase 3 failure can eliminate billions in market value overnight, particularly for Immunovant programs representing majority of enterprise value
FDA regulatory pathway uncertainty for novel mechanisms of action, with potential for unexpected safety signals, clinical holds, or requirement for additional trials extending timelines 2-3 years
Holding company discount - market typically values sum-of-parts at 20-40% discount to standalone subsidiary valuations due to corporate overhead and capital allocation concerns
Immunovant's batoclimab faces direct competition from Argenx's efgartigimod (already approved for myasthenia gravis) and Johnson & Johnson's nipocalimab in FcRn antagonist space
Large pharmaceutical companies (Roche, Amgen, AbbVie) possess superior resources for clinical development, regulatory navigation, and commercial infrastructure if competing programs advance
Patent expiration risks and potential biosimilar competition if programs reach commercialization, particularly for follow-on FcRn inhibitors
Cash burn of $800M annually with no revenue requires continued equity financing or asset monetization - dilution risk if trials extend beyond current cash runway
Subsidiary financing needs may require Roivant capital injections or result in ownership dilution if subsidiaries raise independently at unfavorable valuations
Concentration risk with Immunovant representing estimated 60-70% of NAV - single program failure would devastate parent company valuation
low - Pre-revenue biotech companies exhibit minimal direct correlation to GDP or consumer spending cycles. Clinical trial timelines and regulatory processes proceed independently of economic conditions. However, severe recessions can impact capital markets access for future financing and reduce pharmaceutical company appetite for business development deals.
Rising interest rates create significant valuation pressure on pre-revenue biotech through higher discount rates applied to distant future cash flows. The company's $30.66 current ratio and minimal debt (0.05 D/E) provide insulation from financing cost increases, but equity valuations compress as risk-free rates rise and investors rotate from speculative growth to income-generating assets. Higher rates also reduce pharmaceutical acquirer willingness to pay premium multiples for early-stage assets.
minimal - With negligible debt and substantial cash reserves, Roivant faces no meaningful credit risk. The company's ability to fund operations depends on equity markets rather than credit availability. However, tightening credit conditions can reduce strategic partner ability to finance large upfront licensing payments.
growth - Attracts speculative biotech investors focused on binary clinical catalysts and multi-bagger potential from successful drug approvals. The 157.7% one-year return and 133% six-month return reflect momentum-driven trading around clinical milestones. Institutional biotech specialists and hedge funds with event-driven strategies dominate the shareholder base. Not suitable for income or value investors given negative cash flow, no dividends, and valuation based entirely on discounted future optionality.
high - Pre-revenue biotech with binary clinical catalysts exhibits extreme volatility. Single-day moves of 20-40% common around trial data releases. The recent 34.1% three-month return demonstrates momentum characteristics. Estimated beta above 1.5 relative to broader market, with sector-specific volatility driven by FDA policy changes, competitor data, and risk appetite for speculative growth.